Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERBB2/HOXB13 co-amplification with interstitial loss of BRCA1 defines a unique subset of breast cancers.

Breast cancer research : BCR - 18 Dec 2024

Mitsiades Irene Rin, Onozato Maristela, Iafrate A John, Hicks Daniel, Gülhan Doğa C, Sgroi Dennis C, Rheinbay Esther

Abstract excerpt

BACKGROUND: The HOXB13/IL17RB gene expression biomarker has been shown to predict response to adjuvant and extended endocrine therapy in patients with early-stage ER+ HER2- breast tumors. HOXB13 gene expression is the primary determinant driving the prognostic and endocrine treatment-predictive performance of the biomarker. Currently, there is limited data on HOXB13 expression in HER2+ and ER- breast cancers....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to Gene Amplification

Share to Gene Expression Regulation, Neoplastic

Share to Homeodomain Proteins

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Source

Open in PubMed Open full text

Identifiers

PMID: 39695741
DOI: 10.1186/s13058-024-01943-1
PMCID: PMC11657829

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERBB2/HOXB13 co-amplification with interstitial loss of BRCA1 defines a unique subset of breast cancers.PMID 39695741Read ↗

<i>ERBB2</i> / <i>HOXB13</i> co-amplification with interstitial deletion of <i>BRCA1</i> defines a unique subset of breast cancersSemantic proximity Read ↗

ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.Semantic proximity Read ↗

Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug responseSemantic proximity Read ↗

Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug responseSemantic proximity Read ↗

DNA amplifications in breast cancer: genotypic-phenotypic correlations.Semantic proximity Read ↗

IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target.Semantic proximity Read ↗

Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.Semantic proximity Read ↗

Genomic Characterization of Primary Invasive Lobular Breast Cancer.Semantic proximity Read ↗

Pan-cancer exploration of oncogenic and clinical impacts revealed that HOXA9 is a diagnostic indicator of tumorigenesisSemantic proximity Read ↗

APOBEC3B mRNA Expression in Breast Cancer Correlates with Genomic Mutational SignaturesSemantic proximity Read ↗

IKZF3 amplification frequently occurs in HER2 positive breast cancer and is a potential therapeutic targetSemantic proximity Read ↗

The 11q13-q14 amplicon: clinicopathological correlations and potential drivers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.